Key result
A Community Pharmacist-led Anticoagulation Management Service (CPAMS) improves time in therapeutic range and is cost-effective compared to usual care for warfarin and NOACs.
Why the study?
With the advent of NOAC medications, clinicians and payors questioned whether warfarin still had a role, prompting examination of anticoagulation management systems.
Does a Community Pharmacist-led Anticoagulation Management Service improve time in therapeutic range and cost-effectiveness compared to usual care in patients requiring anticoagulation?
Does a Community Pharmacist-led Anticoagulation Management Service improve time in therapeutic range and cost-effectiveness compared to usual care in patients requiring anticoagulation?
A community pharmacist-led anticoagulation management service using point-of-care INR testing may improve time in therapeutic range and offer a cost-effective alternative to usual care.
Hypothesis-generating for CPAMS in anticoagulation care; prospective randomized trials needed before widespread adoption.
For over 60 years, warfarin has been the treatment of choice in the prevention of strokes and other thromboembolic events. In recent years, a new class of Novel Oral Anticoagulant (NOAC) medication has become available, leaving clinicians and health system payors to question whether warfarin continues to have a place in therapy. This article argues that it may not be the medication that should be in question but instead the systems in place to manage anticoagulation for the patients who need it. Usual Care (UC) for warfarin management has traditionally required multiple healthcare visits, blood collection visits, and laboratory analysis of International Normalized Ratio (INR) with results to then later be relayed to the patient along with dosage adjustments. The article reviews a new model of care, Community Pharmacist-led Anticoagulation Management Service (CPAMS), in which patients receive a point-of-care INR test along with a pharmacist assessment at a pharmacy and results within minutes. Pharmacists then prescribe dosage adjustments immediately, counsel patients, and provide supporting adherence tools such as a colourful picture-based dosing calendar, created by the decision support tool, INR Online. The Nova Scotia CPAMS Demonstration Project shows that this model will result in efficiencies for healthcare providers and optimal anticoagulation with improved time in therapeutic range outcomes for patients. In addition, the CPAMS Costing Study finds the model to be a cost-effective solution for health systems when compared to UC for warfarin as well as NOAC patients.
No takes yet. Share an insight, caveat, or question.
Woodill et al. (2020) conducted a review in Anticoagulation management. Community Pharmacist-led Anticoagulation Management Service (CPAMS) vs. Usual Care (UC) for warfarin and NOACs was evaluated on Time in therapeutic range and cost-effectiveness. A Community Pharmacist-led Anticoagulation Management Service (CPAMS) improves time in therapeutic range and is cost-effective compared to usual care for warfarin and NOACs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: